STOCK TITAN

Medline prices 60M-share secondary offering at $35.50

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Medline Inc. (MDLN) announced pricing of a secondary offering of 60,000,000 Class A common shares at $35.50 per share by selling stockholders. The stockholders granted underwriters a 30-day option to buy up to 9,000,000 additional shares. The offering is expected to close November 23, 2026, subject to customary closing conditions. The selling stockholders are expected to receive approximately $2.1 billion in net proceeds, excluding exercise of the option; Medline will not receive any proceeds from the sale.

Separately, Medline and Medline Holdings, LP agreed to repurchase $200 million of Class A common stock and limited partnership interests directly from selling stockholders in a private, non-underwritten transaction, at a price per equity interest equal to the price paid by underwriters in the offering. The repurchase is expected to close concurrently and is conditioned on the offering closing; the offering is not conditioned on the repurchase. If Common Units are repurchased, sellers will transfer an equivalent number of Class B shares to Medline for no additional consideration, and those shares will be cancelled and retired. The Audit Committee approved the repurchase, which counts toward Medline's previously announced share repurchase program.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Shares in secondary offering 60,000,000 shares Class A common stock offered by selling stockholders
Public offering price $35.50 per share Price to the public for the secondary offering
Underwriters' option Up to 9,000,000 shares 30-day option to purchase additional Class A shares
Net proceeds to selling stockholders Approximately $2.1 billion Expected proceeds, excluding exercise of the underwriters' option
Repurchase amount $200 million Aggregate value of Class A common stock and limited partnership interests to be repurchased
Expected offering closing November 23, 2026 Subject to customary closing conditions
underwritten secondary offering financial
"an underwritten secondary offering of 60,000,000 shares"
An underwritten secondary offering is when existing shareholders sell a block of already-issued shares and an investment bank agrees to buy and resell them to the public, guaranteeing the sale will go through. Think of it as a store owner pre-selling a large shipment to a wholesaler who then sells it to customers; for investors, it can increase the number of shares available, affect short-term price pressure, and signal that insiders are taking profits or diversifying holdings.
Common Units financial
"the repurchase of Common Units"
Common units are the basic ownership stakes in a company, limited partnership, or trust that function like common stock: they give holders a claim on profits and often voting rights. Think of them as the ordinary seats at a table—the most directly affected by the business’s success or failure, so they typically offer higher upside but carry greater risk than preferred claims or creditors, which matters to investors evaluating potential return and safety.
private, non-underwritten transaction financial
"in a private, non-underwritten transaction"
30-day option financial
"a 30-day option to purchase up to an additional 9,000,000 shares"
net proceeds financial
"expected to result in net proceeds to the Selling Stockholders"
The amount of money a company actually keeps from a sale or fundraising after paying all direct costs and fees, similar to take-home pay after taxes and deductions. Investors care because net proceeds determine how much cash is available for things that affect value—paying debt, funding projects, buying assets, or returning money to shareholders—so it influences future growth potential and financial health.
bookrunning managers financial
"acting as bookrunning managers"
Lead banks that organize and manage a new stock or bond offering, coordinating other banks, setting the initial sale price, collecting investor orders and deciding how many shares each buyer receives. Think of them as the project manager and ticket-seller for a public offering — their pricing, allocations and ability to sell the issue directly affect how successful the offering is and how the security performs for investors afterward.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many MDLN shares are being offered, and at what price?

The secondary offering covers 60,000,000 Class A shares at $35.50 per share, sold by the selling stockholders.

How much does Medline receive from the MDLN secondary offering?

Medline will receive no proceeds from the sale; the selling stockholders are expected to receive approximately $2.1 billion in net proceeds, excluding exercise of the underwriters' 30-day option to buy up to 9,000,000 additional shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false000204638600020463862026-11-162026-11-16

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2026

Medline Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-43022

33-1845288

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 

3 Lakes Drive
Northfield, IL 60093

(Address of principal executive offices and zip code)

(847) 949-5500

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

❑ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

❑ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

❑ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

❑ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A common stock, par value $0.0001 per share

MDLN

Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging growth company ❑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ❑

 


Item 1.01 Entry into a Material Definitive Agreement.

On November 16, 2026, Medline Inc. (the “Company”) and Medline Holdings, LP (“Medline Holdings”) entered into a share and unit repurchase agreement (the “Repurchase Agreement”) with certain entities affiliated with Blackstone Inc., The Carlyle Group Inc., and Hellman & Friedman LLC, along with GIC Private Limited and its managed affiliate and a wholly owned subsidiary of the Abu Dhabi Investment Authority (collectively, the “Selling Stockholders”), pursuant to which the Company and Medline Holdings agreed to repurchase directly from the Selling Stockholders an aggregate of $200 million of Class A common stock of the Company and limited partnership interests of Medline Holdings (“Common Units”) in a private, non-underwritten transaction (the “Repurchase”), at a price per equity interest equal to the price paid by the underwriters in the Offering (as defined below). To the extent that Common Units are repurchased from a Selling Stockholder, upon closing of the Repurchase, such Selling Stockholder will also transfer an equivalent number of shares of the Company’s Class B common stock to the Company for no additional consideration, and such shares of Class B common stock will be cancelled and retired.

The Repurchase is expected to close concurrently with the Offering and is conditioned upon the closing of the Offering. The closing of the Offering is not conditioned upon the closing of the Repurchase. The Repurchase has been approved by the Audit Committee of the Company’s Board of Directors, which consists solely of independent directors, and is pursuant to, and will count toward, the Company’s previously announced share repurchase program.

Each of the Selling Stockholders, other than the wholly owned subsidiary of the Abu Dhabi Investment Authority, beneficially owns more than 5% of the Company’s Class A common stock. Additionally, certain of the Selling Stockholders have various other relationships with the Company. For further information concerning material relationships between the Company and such entities and their affiliates, see the section entitled “Certain Relationships and Related Person Transactions” in the Company’s proxy statement filed with the Securities and Exchange Commission on April 23, 2026.

The foregoing description of the Repurchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Repurchase Agreement, which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.

Item 8.01 Other Events.

On November 17, 2026, the Company issued a press release that announced the pricing of an underwritten secondary offering (the “Offering”) of 60,000,000 shares of the Company’s Class A common stock (the “Shares”). The Shares were offered by the Selling Stockholders, and the Offering is expected to result in net proceeds to the Selling Stockholders of approximately $2.1 billion (excluding any exercise of the underwriters’ 30-day option to purchase up to an additional 9,000,000 Shares). The Offering is expected to close on November 23, 2026, subject to customary closing conditions. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

10.1

Share and Unit Repurchase Agreement, dated November 16, 2026, by and among Medline Inc., Medline Holdings, LP, and each of the entities identified on Schedule I thereto.

99.1

Press release of Medline Inc., dated November 17, 2026.

104

The Cover Page of Medline Inc.’s Current Report on Form 8-K dated November 18, 2026, formatted in Inline XBRL.

 

 


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 18, 2026

MEDLINE INC.

 

By: /s/ Michael B. Drazin

Name: Michael B. Drazin

Title: Chief Financial Officer

 

 


Exhibit 99.1img87519852_0.gif

 

img87519852_1.gif

img87519852_2.gif

img87519852_3.gif

img87519852_4.gif

Medline Inc. announces pricing of secondary offering of Class A common stock

 

Northfield, Ill., November 17, 2026 (GLOBE NEWSWIRE) – Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of its secondary offering of 60,000,000 shares of Medline’s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC along with GIC Private Limited and its managed affiliate and a wholly owned subsidiary of the Abu Dhabi Investment Authority (collectively, the “Selling Stockholders”) at a price to the public of $35.50 per share (the “Offering”). The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 9,000,000 shares of Medline’s Class A common stock. The Offering is expected to close on November 23, 2026, subject to customary closing conditions.

 

Medline is not selling any shares of Class A common stock in the Offering and will not receive any of the proceeds from the sale.

 

Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities and J.P. Morgan are acting as global coordinators and joint bookrunning managers. Barclays, Citigroup, Deutsche Bank Securities, Jefferies, UBS Investment Bank, Evercore ISI, BMO Capital Markets, BNP Paribas, MUFG, RBC Capital Markets, Santander, Societe Generale, TD Cowen, Wells Fargo Securities, Wolfe | Nomura Alliance, Leerink Partners, Macquarie Capital, Mizuho, Piper Sandler, Truist Securities and William Blair are acting as bookrunning managers, and Blackstone Capital Markets, Carlyle, Baird, Rothschild & Co, Stifel, BTIG, ING, IMI – Intesa Sanpaolo, NCMG, Perella Weinberg, Academy Securities, Blaylock Van, LLC, C.L. King & Associates, Drexel Hamilton, Loop Capital Markets, Mischler AmeriVet, R. Seelaus & Co., LLC, Ramirez & Co., Inc., Siebert Williams Shank and Tigress Financial Partners are acting as co-managers for the Offering.

 

The Offering of these securities is being made only by means of a prospectus. When available, copies of the prospectus relating to this Offering may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526, or by email at prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at prospectus@morganstanley.com; BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001 or by email at dg.prospectus_requests@bofa.com; and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com.

 

In addition, as previously announced, Medline and Medline Holdings, LP (“Medline Holdings”) have agreed to repurchase an aggregate of $200 million of Medline’s Class A common stock and limited partnership interests of Medline Holdings (“Common Units”) directly from the Selling Stockholders in a private, non-underwritten transaction at a price per equity interest equal to the price paid by the underwriters in the Offering (the “Repurchase”). To the extent that Common Units are repurchased from a Selling Stockholder, upon closing of the Repurchase, such Selling Stockholder will also transfer an equivalent number of shares of Medline’s Class B common stock to Medline for no additional consideration, and such shares of Class B common stock will be cancelled and retired. The Repurchase is expected to close concurrently with the Offering and is conditioned upon the closing of the Offering. The closing of the Offering is not conditioned upon the closing of the Repurchase. The Repurchase has been approved by the Audit Committee of Medline’s Board of Directors and is pursuant to, and will count toward, Medline’s previously announced share repurchase program.

 

 


 

A registration statement relating to these securities was filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”). This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

 

About Medline

Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its broad product portfolio, resilient supply chain and leading clinical solutions, Medline helps healthcare providers improve their clinical, financial and operational outcomes. Headquartered in Northfield, Ill., the company employs more than 45,000 people worldwide and operates in more than 100 countries.

 

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Words such as “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “foreseeable,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “seek,” “should,” “will,” or “would,” or similar conditional or future expressions, are intended to identify forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements related to Medline’s industry, business strategy, costs, and cost savings, goals and expectations, market position, future operations, margins, profitability, annual guidance, and other financial and operating information. The forward-looking statements are based on management’s current expectations and are subject to various risks, uncertainties, and changes in circumstances, many of which are beyond Medline’s control, that could cause actual results to differ materially.

Although we believe that the assumptions underlying the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include but are not limited to those described under “Risk Factors” in Medline’s registration statement on Form S-1, as amended, relating to the Offering and “Item 1A. Risk Factors” in Medline’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC, as such factors may be updated from time to time in Medline’s periodic filings with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Medline’s filings with the SEC. Except as otherwise required by law, we disclaim any intent or obligation to update any “forward-looking statement” made in this press release to reflect changed assumptions, the occurrence of unanticipated events, or changes to future operating results over time.

 

Contacts:

Investor relations:

Karen King

Global Head, Investor Relations

 

Patrick Flaherty

Director, Investor Relations

 

+1.847.247.7222

IR@medline.com

 

Media relations:

Ben Fox

Vice President, Corporate Communications

+1.224.327.9999

media@medline.com

 

Source: Medline Inc.

 


Filing Exhibits & Attachments

3 documents

Keep reading